Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 3/20 | 0.53 |
| ▸ | CTSL | P07711 | 3/20 | 0.53 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.52 |
| ▸ | APOL1 | O14791 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | AS3MT | Q9HBK9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4144103 | 0.93 | CTSV (0.47) | CTSVCTSLTRPM8APOL1MAOA | |
| SCHEMBL29652545 | 0.93 | TRPM8 (0.56) | CTSVCTSLTRPM8MAOAMAOB | |
| SCHEMBL102598 | 0.93 | TRPM8 (0.56) | CTSVCTSLTRPM8MAOAMAOB | |
| SCHEMBL4151637 | 0.91 | TRPM8 (0.57) | CTSVCTSLTRPM8MAOAMAOB | |
| SCHEMBL4156633 | 0.90 | TRPM8 (0.54) | CTSVCTSLTRPM8MAOAMAOB | |
| SCHEMBL4155146 | 0.89 | TRPM8 (0.53) | CTSVCTSLTRPM8MAOAMAOB | |
| SCHEMBL4158966 | 0.88 | TRPM8 (0.52) | CTSVCTSLTRPM8MAOAMAOB | |
| SCHEMBL19949651 | 0.88 | TRPM8 (0.52) | CTSVCTSLTRPM8MAOAMAOB | |
| SCHEMBL4144271 | 0.88 | TRPM8 (0.52) | CTSVCTSLTRPM8MAOAMAOB | |
| SCHEMBL4156625 | 0.87 | TRPM8 (0.49) | CTSVCTSLTRPM8MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10036347-A | — | — | None | — | — | JP | disclosed |
| EP-3512842-B1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS INC (US) | 2024-01-17 | — | — | EP | disclosed |
| EP-3512842-B1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS INC (US) | 2024-01-17 | — | — | EP | disclosed |
| WO-2023023531-A1 | ESTROGEN RECEPTOR DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023023531-A1 | ESTROGEN RECEPTOR DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-11584743-B2 | Indole derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-11584743-B2 | Indole derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210040081-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. | 2021-02-11 | — | — | US | disclosed |
| US-20210040081-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. | 2021-02-11 | — | — | US | disclosed |
| US-10865202-B2 | Indole derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-07-13 | — | — | US | disclosed |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2016097071-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-06-23 | — | — | WO | disclosed |
| CN-1103756-C | Estrogenic agents | WYETH HOME PRODUCTS CORP (US) | 2003-03-26 | — | — | CN | disclosed |
| CN-1309637-A | Compositions comprising 2-phenyl-indole compounds and estrogen formutations | AMERICAN HOME PROD (US) | 2001-08-22 | — | — | CN | disclosed |
| JP-H1036347-A | ESTROGENLIKE AGENT | AMERICAN HOME PROD CORP | 1998-02-10 | — | — | JP | disclosed |
| CN-1168373-A | Estrogenic agents | AMERICAN HOME PROD (US) | 1997-12-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210040081-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESR1, GPER1, ESR2 | CTSV 1858/4885CTSL 2781/4885TRPM8 319/4885 |
| US-10865202-B2 | Indole derivatives as estrogen receptor degraders | ESR1, GPER1, ESR2 | CTSV 1858/4885CTSL 2781/4885TRPM8 319/4885 |
| US-11584743-B2 | Indole derivatives as estrogen receptor degraders | ESR1, GPER1, ESR2 | CTSV 1858/4885CTSL 2781/4885TRPM8 319/4885 |
| US-20170197915-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESR1, GPER1 | CTSV 4241/4885CTSL 4179/4885TRPM8 463/4885 |
| US-20160304450-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESR1, GPER1 | CTSV 4241/4885CTSL 4179/4885TRPM8 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.